Emyria and MMA launch MDMA-assisted therapy program for PTSD
Filed with ASX · · 6 pages · English
● Emyria and Mind Medicine Australia announce their first psychedelic-assisted therapy care program (EMDMA-001) for sufferers of treatment resistant post traumatic stress disorder (PTSD) ● EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS) ● Pending successful ethics review and the finalisation of all logistic
Earlier from Emyria
- $5m Placement for Drug Registration and Treatment Pipeline
- Emyria and Cann Partner to Register CBD Product
- Emyria Adds Second Clinical Site in Perth
- Emyria adds second Emerald Clinic in Melbourne
- Emyria wins digital health monitoring grant with UWA
Later from Emyria
- Emyria Obtains TGA Approval for Medical Grade Monitoring App
- Emyria Data Validated, Care Model Reduces Opioids
- Emyria Advances EMD-004 Program Towards Registration
- Emyria to Develop Novel Psychedelics Pipeline with UWA
- Emyria Executes Pure CBD Agreement with AltaSciences
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria